{"id":7589,"date":"2025-12-07T08:00:54","date_gmt":"2025-12-07T07:00:54","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7589"},"modified":"2025-12-07T14:00:16","modified_gmt":"2025-12-07T13:00:16","slug":"phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7589\/phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt\/","title":{"rendered":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,686,629,703,769,691,690,594,781,623,655,595],"class_list":["post-7589","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bgb-16673","post-tag-btk","post-tag-btk-degrader","post-tag-cadance-101","post-tag-cdac","post-tag-chimeric-degradation-activation-compound","post-tag-chronic-lymphocytic-leukemia","post-tag-cll-sll","post-tag-richters-transformation","post-tag-rt","post-tag-small-lymphocytic-lymphoma","congress_resource_type-poster","content_type-reading","molecule-bgb-16673"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":true,"key_data_presentation_only":false,"key_data_presentation_prioritization":10,"tags":[704,760,781,594,595,655,623,686,629,703,691,690,769],"visible_tags":[704,655,686],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis study evaluated BGB-16673, an investigational drug that degrades the BTK protein, in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), whose disease had transformed into a more aggressive form (Richter transformation) and who had tried several prior treatments. Among 24 patients, BGB-16673 was generally tolerable, with manageable side effects. Two-thirds of patients had grade \u22653 treatment-emergent adverse events (TEAEs). TEAEs of any grade that occurred in \u226515% of patients were decreased neutrophil count, nausea, diarrhea, peripheral edema, and pneumonia. One death occurred but was a result to the disease progressing, not due to treatment. About half responded to treatment, with some responses lasting more than six months. Responses were also observed in patients with high-risk genetic mutations. These results support further investigation of BGB-16673 in Richter transformation.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis study evaluated BGB-16673, an investigational drug that degrades the BTK protein, in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), whose disease had transformed into a more aggressive form (Richter transformation) and who had tried several prior treatments. Among 24 patients, BGB-16673 was generally tolerable, with manageable side effects. Two-thirds of patients had grade \u22653 treatment-emergent adverse events (TEAEs). TEAEs of any grade that occurred in \u226515% of patients were decreased neutrophil count, nausea, diarrhea, peripheral edema, and pneumonia. One death occurred but was a result to the disease progressing, not due to treatment. About half responded to treatment, with some responses lasting more than six months. Responses were also observed in patients with high-risk genetic mutations. These results support further investigation of BGB-16673 in Richter transformation.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295814","authors":[6585],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Read the ASH 2025 poster on preliminary results from ongoing phase 1 CaDAnCe-101 study of BGB-16673 in R\/R RT by Meghan C. Thompson et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/10\/ASH2025_phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295814\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-07\",  \r\n  \"keywords\": [\"bgb 16673 in richter transformation\", \"cadance-101 in rr rt\", \"Richter transformation BTK degrader trial\", \"BGB-16673 treatment response for RT patients\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Meghan C. Thompson, MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Read the ASH 2025 poster on preliminary results from ongoing phase 1 CaDAnCe-101 study of BGB-16673 in R\/R RT by Meghan C. Thompson et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/6585"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/769"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/690"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/691"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/703"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/629"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/686"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/623"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/655"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/595"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/781"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7589"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}